Leap Therapeutics Inc (NASDAQ:LPTX) – Stock analysts at Piper Sandler issued their Q2 2020 earnings estimates for Leap Therapeutics in a research note issued on Monday, June 29th. Piper Sandler analyst T. Van. Buren forecasts that the company will earn ($0.25) per share for the quarter. Piper Sandler currently has a “Overweight” rating and a $6.00 price target on the stock. Piper Sandler also issued estimates for Leap Therapeutics’ Q3 2020 earnings at ($0.15) EPS, Q4 2020 earnings at ($0.20) EPS, FY2020 earnings at ($1.00) EPS, Q1 2021 earnings at ($0.15) EPS, Q2 2021 earnings at ($0.20) EPS, Q3 2021 earnings at ($0.20) EPS, Q4 2021 earnings at ($0.20) EPS, FY2021 earnings at ($0.75) EPS, FY2022 earnings at ($0.95) EPS, FY2023 earnings at ($1.15) EPS and FY2024 earnings at ($1.55) EPS.
Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.31). The business had revenue of $0.38 million for the quarter.
LPTX has been the topic of several other reports. Zacks Investment Research lowered shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Raymond James set a $2.50 target price on shares of Leap Therapeutics and gave the company an “outperform” rating in a research report on Friday, June 12th. HC Wainwright reiterated a “buy” rating and set a $5.00 target price (up from $2.50) on shares of Leap Therapeutics in a research report on Tuesday, May 19th. Finally, ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, May 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $4.15.
NASDAQ LPTX opened at $2.18 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.82 and a current ratio of 2.82. The company’s fifty day moving average is $2.32 and its two-hundred day moving average is $1.92. Leap Therapeutics has a 52-week low of $0.57 and a 52-week high of $3.18.
Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Leap Therapeutics by 21.5% during the 1st quarter. BlackRock Inc. now owns 38,946 shares of the company’s stock valued at $62,000 after purchasing an additional 6,897 shares during the last quarter. Personal CFO Solutions LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $101,000. Perceptive Advisors LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $10,627,000. Gratus Capital LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $40,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Leap Therapeutics in the first quarter worth about $948,000. 31.38% of the stock is owned by hedge funds and other institutional investors.
In other news, major shareholder Perceptive Advisors Llc purchased 1,750,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $2.00 per share, with a total value of $3,500,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 25.89% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Story: What is a dead cat bounce?
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.